Insight Molecular Diagnostics (IMDX) Aperçu de l'action
Insight Molecular Diagnostics Inc. est une société de diagnostic de précision qui opère aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
IMDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Insight Molecular Diagnostics Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$4.85 |
| Plus haut sur 52 semaines | US$8.51 |
| Plus bas sur 52 semaines | US$2.33 |
| Bêta | 1.76 |
| Variation sur 1 mois | -17.09% |
| Variation sur 3 mois | 53.00% |
| Variation sur 1 an | 67.82% |
| Variation sur 3 ans | 12.27% |
| Variation sur 5 ans | -95.48% |
| Évolution depuis l'introduction en bourse | -96.12% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 08
IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns
Analysts have raised their fair value estimate for Insight Molecular Diagnostics from $9.00 to $12.00, citing updated assumptions around revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Insight Molecular Diagnostics Insight Molecular Diagnostics reported an online publication in Clinical Chemistry highlighting high concordance between its digital PCR based GraftAssure transplant monitoring test and a next generation sequencing assay for donor derived cell free DNA in kidney transplant patients, with agreement of 99.2% at the 0.5% dd cfDNA threshold.
Mise à jour du récit • Jun 24
IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics to $8.33. This reflects updated assumptions on the discount rate, profit margin, and future P/E, while keeping the fair value estimate unchanged at $8.33.Mise à jour du récit • Jun 06
IMDX: FDA Review Of Transplant Rejection Test Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics from $10.50 to about $8.33, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Insight Molecular Diagnostics submitted its GraftAssureDx donor derived cell free DNA (dd cfDNA) assay kit to the FDA for regulatory review, following 12 years of clinical development and three years of focused product work.Recent updates
Mise à jour du récit • Jul 08
IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns
Analysts have raised their fair value estimate for Insight Molecular Diagnostics from $9.00 to $12.00, citing updated assumptions around revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Insight Molecular Diagnostics Insight Molecular Diagnostics reported an online publication in Clinical Chemistry highlighting high concordance between its digital PCR based GraftAssure transplant monitoring test and a next generation sequencing assay for donor derived cell free DNA in kidney transplant patients, with agreement of 99.2% at the 0.5% dd cfDNA threshold.Mise à jour du récit • Jun 24
IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics to $8.33. This reflects updated assumptions on the discount rate, profit margin, and future P/E, while keeping the fair value estimate unchanged at $8.33.Mise à jour du récit • Jun 06
IMDX: FDA Review Of Transplant Rejection Test Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics from $10.50 to about $8.33, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Insight Molecular Diagnostics submitted its GraftAssureDx donor derived cell free DNA (dd cfDNA) assay kit to the FDA for regulatory review, following 12 years of clinical development and three years of focused product work.Article d’analyse • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Mise à jour du récit • May 15
IMDX: FDA Submission And Strengthened Cash Position Will Drive Bullish Repricing
Insight Molecular Diagnostics' analyst price target has moved from $8 to $12, with analysts pointing to secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key factors supporting this revision. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$12 price target as reflecting reduced funding risk after the recent US$26M offering, which they see as supportive for execution on pending milestones.Mise à jour du récit • Apr 28
IMDX: Upcoming FDA Review And Cash Cushion May Support Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recently completed $26M offering, which secures cash beyond a potential GraftAssureDx approval and an expected FDA submission in the coming weeks, as key drivers of their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the new $12 price target as reflecting improved funding visibility, with the recent $26M offering seen as supportive of ongoing operations past a potential GraftAssureDx approval.Mise à jour du récit • Apr 13
IMDX: Upcoming FDA Submission And Cash Runway May Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26M capital raise and expectations around an upcoming FDA submission for GraftAssureDx as key supports for the new outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$12 price target as reflecting higher confidence that the recent US$26M capital raise supports the company through key regulatory milestones.Mise à jour du récit • Mar 29
IMDX: Upcoming FDA Review And Capital Raise Will Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26,000,000 capital raise and the expected FDA submission for GraftAssureDx in the coming weeks as key factors supporting the revised target. Analyst Commentary Recent research updates give you a clearer picture of how the Street is reacting to Insight Molecular Diagnostics after its latest funding and upcoming regulatory milestones.Mise à jour du récit • Mar 12
IMDX: Upcoming FDA Submission And Capital Raise Will Drive Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26m capital raise and expectations for an upcoming FDA submission for GraftAssureDx as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the move in the price target to $12 as reflecting higher confidence that the recent $26m capital raise supports the company through key regulatory milestones.Mise à jour du récit • Feb 26
IMDX: Funding And Upcoming FDA Submission Will Shape Potential Upside
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key supports for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a $12 price target as reflecting higher conviction that the current funding and product plan can support the company through key milestones.Mise à jour du récit • Feb 11
IMDX: Stable Outlook As Regulatory And Transplant Center Expansion Will Shape Upside
Analysts have adjusted their price target on Insight Molecular Diagnostics to reflect an updated fair value of $7.00 per share, a higher assumed future P/E of 121.71, and revised views on the discount rate and profit margin potential. What's in the News Year-end business update outlined commercial progress and the clinical trial status of the GraftAssureDx test kit, including preparation for an in vitro diagnostic de novo submission to the US Food & Drug Administration (FDA).Mise à jour du récit • Jan 27
IMDX: Stable Outlook As Regulatory Progress And Transplant Testing Portfolio Will Shape Upside
Analysts have nudged their price target on Insight Molecular Diagnostics higher to reflect slightly refined assumptions on discount rate, profit margin and forward P/E. The updated target is now framed around a fair value of 7.0. What's in the News Year end business update outlines commercial progress for the GraftAssureDx test kit, including clinical trial status and plans for an in vitro diagnostic de novo submission to the United States Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026 (company update).Mise à jour du récit • Jan 12
IMDX: Stable Outlook As Transplant Monitoring Pipeline And Regulatory Progress Will Support Upside
Narrative Update on Insight Molecular Diagnostics Analysts have slightly adjusted their price target on Insight Molecular Diagnostics, with the change reflecting updated fair value modeling around a 7.0% discount rate, approximately 41% revenue growth assumptions, a 16.24% profit margin, and a forward P/E near 120x. What's in the News Year end business update provided on commercial progress, including the GraftAssureDx test kit clinical trial and plans for an in vitro diagnostic de novo submission to the US Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026.Mise à jour du récit • Dec 25
IMDX: Transplant Monitoring Expansion Will Drive Future Market Leadership
Analysts have modestly raised their price target on Insight Molecular Diagnostics to reflect incremental improvements in long term profit margin assumptions and a slightly lower discount rate, while maintaining broadly consistent growth expectations and valuation multiples. What's in the News Publication of a case study in the American Journal of Transplantation highlighted Insight Molecular Diagnostics' GraftAssure assay as essential for monitoring a high risk kidney transplant patient undergoing novel CD19 CAR T therapy without traditional immunosuppression (Key Developments).Mise à jour du récit • Dec 11
IMDX: Transplant Monitoring Advances Will Drive Future Market Momentum
Narrative Update on Insight Molecular Diagnostics The analyst price target for Insight Molecular Diagnostics has been modestly revised upward by analysts, reflecting slightly higher fair value estimates supported by incremental improvements in projected discount rate, revenue growth, profit margin, and future price to earnings assumptions. What's in the News A published clinical study in the American Journal of Transplantation highlighted the GraftAssure assay as critical for long-term monitoring of a high-risk kidney transplant patient treated with novel CD19 CAR T therapy, confirming absence of rejection during cancer treatment (American Journal of Transplantation).Mise à jour du récit • Nov 27
IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum
Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).Seeking Alpha • Nov 14
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Summary Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. Read the full article on Seeking AlphaArticle d’analyse • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Mise à jour du récit • Nov 12
IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance
Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.
Nouveau récit • Apr 13
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Rendement pour les actionnaires
| IMDX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -15.5% | 0.02% | 0.6% |
| 1Y | 67.8% | 36.1% | 19.5% |
Rendement vs Industrie: IMDX a dépassé le secteur US Biotechs qui a rapporté 36.1 % au cours de l'année écoulée.
Rendement vs marché: IMDX a dépassé le marché US qui a rapporté 19.5 % au cours de l'année écoulée.
Volatilité des prix
| IMDX volatility | |
|---|---|
| IMDX Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de IMDX a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de IMDX ( 18% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2009 | 57 | Josh Riggs | www.imdxinc.com |
Insight Molecular Diagnostics Inc. est une société de diagnostic de précision qui opère aux États-Unis et dans le monde entier. La société développe et commercialise des tests développés en laboratoire, des tests en kit à usage exclusif de la recherche et des tests cliniques en kit. Elle développe DetermaCNI, un outil de surveillance sanguine qui détecte la progression précoce après un cycle de traitement du cancer, et DetermaIO, un test d'expression génique qui évalue le microenvironnement tumoral pour prédire la réponse aux immunothérapies.
Insight Molecular Diagnostics Inc. Résumé des fondamentaux
| IMDX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$154.67m |
| Bénéfices(TTM) | -US$47.84m |
| Recettes(TTM) | US$1.95m |
80.4x
Ratio P/S-3.3x
Ratio P/ELe site IMDX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IMDX compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.95m |
| Coût des recettes | US$954.00k |
| Marge brute | US$995.00k |
| Autres dépenses | US$48.84m |
| Les revenus | -US$47.84m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.48 |
| Marge brute | 51.05% |
| Marge bénéficiaire nette | -2,454.64% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de IMDX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/09 10:30 |
| Cours de l'action en fin de journée | 2026/07/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Insight Molecular Diagnostics Inc. est couverte par 8 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| null null | KeyBanc Capital Markets Inc. |